mouthwash news24 Aug 2020 08:12
I
4/08/2020 7:00am
UK Regulatory (RNS & others)
Venture Life (LSE:VLG)
Intraday Stock Chart
Monday 24 August 2020
Click Here for more Venture Life Charts.
TIDMVLG
RNS Number : 8936W
Venture Life Group PLC
24 August 2020
24 August 2020
VENTURE LIFE GROUP PLC
("Venture Life" "VLG" or the "Group")
Venture Life's leading oral care brands participation in UK clinical trial on COVID-19 patients
Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announced on 15 May 2020 that it supported further research into the idea that using mouthwash could reduce the transmission of enveloped viruses such as COVID-19. Today the Company announces its involvement in a UK-led clinical trial on COVID-19 patients, in partnership with Cardiff University. This independent multi-centre clinical study, which is being led by Professor David Thomas at Cardiff University, will investigate the possibility that using over-the-counter mouthwashes could help to reduce the viral load and therefore the transmission of COVID-19 in the mouth. Venture Life is delighted to confirm that its leading mouthwash, Dentyl, will be involved in this UK clinical trial.
A literature review of previous research led by Professor Valerie O'Donnell at Cardiff University and expert input from a group of virologists, microbiocide experts, lipid specialists and healthcare experts from the universities of Cardiff, Nottingham, Ottawa and Barcelona, published in May 2020, suggested the possibility that certain mouthwashes could be used to help reduce transmission of enveloped viruses such as SARS-CoV2, but that more research was needed to test this idea. The review concluded that Cethylpyridinium Chloride (CPC) may be effective in this respect. Venture Life's Dentyl mouthwash, which is currently sold in the UK and eleven other countries, contains CPC as its main active ingredient.
Venture Life is delighted to be partnering with Cardiff University and its affiliates, in order to help facilitate this valuable research. The clinical study entitled 'The measurement of mouthwash anti-viral activity against COVID-19' (MOMA) will be commencing in August and is expected to last for 12 weeks. This is a multi-centre study and will recruit patients currently in hospital with COVID-19, commencing at Cardiff hospital.
Professor David Thomas from Cardiff University commented: "We are very keen to start this much needed clinical trial as our review of the literature indicated that we need to look deeper into the possible positive impact that mouthwashes may play on the transmission of COVID-19. We believe this is an exciting opportunity to determine whether a compound that can inactivate an enveloped virus in a test tube may work in humans, actively shedding the virus in the mouth and throat'.
Jerry Randall, CEO of Venture Life, commented: "We are the only mouthwash manufacturer to be involved in the Cardiff
Sign In
Follow the stocks
